Actinium-225 FAP 2286 - 3B Pharmaceuticals/Novartis
Alternative Names: 225Ac-FAP-2288; 225Actinium-Fibroblast Activation Protein-2286; 2nd Generation alpha-emitter - Clovis Oncology; 225Actinium FAP-2286Latest Information Update: 26 Apr 2023
At a glance
- Originator 3B Pharmaceuticals
- Class Antineoplastics; Peptide drug conjugates; Peptides; Radioisotopes; Radiopharmaceuticals
- Mechanism of Action Ionising radiation emitters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Cancer